Massimiliano Camilli, Marcello Viscovo, Tamara Felici, Luca Maggio, Federico Ballacci, Giacomo Carella, Alice Bonanni, Priscilla Lamendola, Lorenzo Tinti, Antonio Di Renzo, Giulia Coarelli, Eugenio Galli, Giovanna Liuzzo, Francesco Burzotta, Rocco Antonio Montone, Federica Sorà, Simona Sica, Stefan Hohaus, Gaetano Antonio Lanza, Filippo Crea, Antonella Lombardo, Giorgio Minotti
AIMS: Chimeric Antigen Receptor-T (CAR-T) cell infusion is a rapidly evolving antitumor therapy; however, cardiovascular (CV) complications, likely associated with cytokine release syndrome (CRS) and systemic inflammation, have been reported to occur. The CARdio-Tox study aimed at elucidating incidence and determinants of cardiotoxicity related to CAR-T cell therapy. METHODS: Patients with blood malignancies candidate to CAR-T cells were prospectively evaluated by echocardiography at baseline and 7 and 30 days after infusion...
March 27, 2024: Cardio-Oncology